Loading...
•
Mar 31, 2020
Amphastar Q1 2020 Earnings Report
Reported net revenues of $84.7 million and GAAP net income of $3.9 million for the first quarter.
Key Takeaways
Amphastar Pharmaceuticals reported a strong first quarter in 2020, with net revenues of $84.7 million and GAAP net income of $3.9 million, driven by strong sales of Primatene® Mist and hospital products.
Net revenues reached $84.7 million for the first quarter.
GAAP net income was $3.9 million, or $0.08 per share, for the first quarter.
Adjusted non-GAAP net income amounted to $8.4 million, or $0.17 per share, for the first quarter.
Increased sales of Primatene® Mist were driven by successful marketing and pantry loading due to COVID-19.
Revenue by Segment
Forward Guidance
The financial results for the three months ended March 31, 2020, were not significantly impacted by the COVID-19 pandemic, except for the increased sales of Primatene® Mist and some hospital products. It is not possible at this time to estimate the impact that COVID-19 could have on our business, as the impact will depend on future developments, which are highly uncertain and cannot be predicted.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...